BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor
Daniel Meibom, Pierre Wasnaire, Kristin Beyer, Andreas Broehl, Yolanda Cancho‐Grande, Nadine H. Elowe, Kerstin Henninger, Sarah Johannes, Natalia A. Jungmann, Tanja Krainz, Niels Lindner, Stefanie Maassen, Bryan T. MacDonald, Denis Menshykau, Joachim Mittendorf, Guzmán Sánchez, Martina Schaefer, Eric Stefan, Afra Torge, Yi Xing, Dmitry Zubov
Abstract
The matrix metalloprotease ADAMTS7 has been identified by multiple genome-wide association studies as being involved in the development of coronary artery disease. Subsequent research revealed the proteolytic function of the enzyme to be relevant for atherogenesis and restenosis after vessel injury. Based on a publicly known dual ADAMTS4/ADAMTS5 inhibitor, we have in silico designed an ADAMTS7 inhibitor of the catalytic domain, which served as a starting point for an optimization campaign. Initially our inhibitors suffered from low selectivity vs MMP12. An X-ray cocrystal structure inspired us to exploit amino acid differences in the binding site of MMP12 and ADAMTS7 to improve selectivity. Further optimization composed of employing 5-membered heteroaromatic groups as hydantoin substituents to become more potent on ADAMTS7. Finally, fine-tuning of DMPK properties yielded BAY-9835, the first orally bioavailable ADAMTS7 inhibitor. Further optimization to improve selectivity vs ADAMTS12 seems possible, and a respective starting point could be identified.